I-FDA ivuma iFotivda yomhlaza wezintso

I-AVEO Oncology (Nasdaq: AVEO) namhlanje ibhengeze ukuba i-US Food and Drug Administration (FDA) ivume i-FOTIVDA^® (i-tivozanib) yonyango lwabantu abadala abahlaziyiweyo okanye abahlaziyiweyo be-renal cell carcinoma (RCC) abaye bafumana ezimbini okanye ngaphezulu zonyango lwe-systemic ngaphambili. I-FOTIVDA yinto yomlomo, isizukulwana esilandelayo se-vascular endothelial growth factor (VEGF) i-tyrosine kinase inhibitor (TKI).

"Namhlanje ukuvunywa kwe-FOTIVDA kunika isixhobo esitsha sokunyanga izigulane ezinomhlaza wezintso eziye zabuyela kwakhona okanye ziye zaphinda zaphinda zaphinda zaphinda zanyangwa kwiinkqubo ezimbini okanye ngaphezulu," utshilo uBrian Rini, MD, oyiNtloko yovavanyo lwezonyango kwi-Vanderbilt Ingram Cancer Centre kunye nomphandi oyintloko we Ulingo lwe-TIVO-3. 

"Ngenkqubela phambili kunyango lwe-RCC, izigulana zihlala ixesha elide, zinyusa imfuno yonyango oluqinisekisiweyo, olunyamezelwe kakuhle kwimeko ebuyelayo okanye echasayo. Uphononongo lwe-TIVO-3 luphononongo lokuqala olulungileyo lweSigaba sesi-3 kwizigulana ze-RCC ezifumene unyango lwenkqubo ephambili emibini okanye ngaphezulu, kunye neSigaba sesi-3 sokuqala sophononongo lwe-RCC ukubandakanya inani elichazwe kwangaphambili lezigulane ezifumene unyango lwangaphambili, umgangatho wangoku wokhathalelo. kunyango lomgca wangaphambili. Ngale mvume, ndikholelwa ukuba i-FOTIVDA imele ungenelelo olunomtsalane, kwaye ndilindele ukuba idlale indima enentsingiselo kunyango lwe-RCC oluvelayo.

"Sikholelwa kumandla e-FOTIVDA okubonelela ngokhetho olwahlukileyo lonyango kwinani elikhulayo labantu base-US abane-RCC ebuyela umva okanye i-refractory, kwaye namhlanje iphawula isiphelo seminyaka emininzi yokusebenza nzima kunye nokuzimisela kwabantu abaninzi ukuzisa olu nyango kwizigulana, "Utshilo uMichael Bailey, umongameli kunye negosa eliphezulu le-AVEO. "Ngemvume yanamhlanje, i-AVEO iqala uhambo lwayo njengenkampani yenqanaba lezorhwebo, impumelelo ephawulekayo kwishishini lethu. Egameni leqela lonke le-AVEO, ndithanda ukubulela zonke izigulana, iintsapho zabo, kunye nabo babakhathalelayo abamigudu yabo engadinwayo yenze ukuba olu suku lube yimpumelelo.”

"I-RCC ehlaziyiweyo okanye i-refractory yisifo esibuhlungu apho iziphumo zesigulane zinokulinganiselwa ngenxa ye-tradeoff phakathi kokunyamezela kunye nokusebenza kakuhle," kusho uDena Battle, umongameli we-KCCure. "Imvume ye-FDA ye-FOTIVDA imele ukuqhubela phambili okuchulumancisayo, okunentsingiselo ngokubonelela ngokhetho olutsha lonyango kwesi sigulana."

I-AVEO iceba ukwenza i-FOTIVDA ifumaneke kwizigulana zase-US ngo-Matshi 31, 2021.

Ukuvunywa kwe-FOTIVDA kusekwe kuphononongo olungundoqo lwe-AVEO lweSigaba sesi-3, i-TIVO-3, ukuthelekisa i-FOTIVDA kunye ne-sorafenib kwi-RCC ebuyiselweyo okanye e-refractory ephucukileyo elandela iindlela ezimbini okanye ngaphezulu zonyango lwe-systemic. Isicelo sikwaxhaswa zizilingo ezithathu ezongezelelweyo kwi-RCC kwaye zibandakanya idatha yokhuseleko evela kwizifundo zeklinikhi ezingaphezu kwe-1,000.

Izigulana (n=350) ezibhaliswe kuphononongo lwe-TIVO-3 ziye zahlelwa ngokungenamkhethe 1:1 ukufumana nokuba yi-FOTIVDA okanye i-sorafenib. Umlinganiselo ongundoqo wesiphumo esisebenzayo ibikukusinda okungahambelaniyo (progression-free survival) (PFS), evavanywe yikomiti yophononongo lweradiology emfamekileyo. Ezinye iisiphelo ezisebenzayo yayikukusinda ngokubanzi (OS) kunye nezinga lokuphendula lenjongo (ORR).

I-PFS ephakathi yayiyi-5.6 iinyanga (95% CI: 4.8, 7.3) kwingalo ye-FOTIVDA (n = 175) xa kuthelekiswa neenyanga ze-3.9 (95% CI: 3.7, 5.6) kulabo baphathwa nge-sorafenib (HR 0.73; 95% CI: 0.56) , 0.95; p=0.016). I-Median OS yayingu-16.4 (95% CI: 13.4, 21.9) kunye neenyanga ze-19.2 (95% CI: 14.9, 24.2), kwi-FOTIVDA kunye neengalo ze-sorafenib, ngokulandelanayo (HR 0.97; 95% CI: 0.75, 1.24). I-ORR yayiyi-18% (95% CI: 12%, 24%) yengalo yeFOTIVDA kunye ne-8% (95% CI: 4%, 13%) yengalo ye-sorafenib.

Ezona zixhaphakileyo (≥20%) iimpendulo ezingalunganga yayikukudinwa, uxinzelelo lwegazi, urhudo, ukuncipha kokutya, isicaphucaphu, i-dysphonia, i-hypothyroidism, ukukhohlela, kunye ne-stomatitis. Ibakala eliqhelekileyo le-3 okanye i-4 ye-laboratory engaqhelekanga (≥5%) yanciphisa i-sodium, yanda i-lipase, kunye ne-phosphate eyancipha.

I-dose ye-tivozanib ephakanyisiweyo yi-1.34 mg kanye ngosuku kunye okanye ngaphandle kokutya kweentsuku ze-21 zonke iintsuku ze-28 kunyango olulandelwa yi-7 yeentsuku zonyango (umjikelezo weentsuku ze-28) de kube ukuqhubela phambili kwesifo okanye ubuthi obungamkelekanga.

IFowuni yeNkomfa kunye nolwazi lweWebcast

Ngokunxulumene nesi sibhengezo, i-AVEO iya kubamba umnxeba wenkomfa kunye nesilayidi sewebhu namhlanje, ngoMatshi 10, 2021, ngo-6: 00 PM Ixesha laseMpuma. Umnxeba unokufumaneka ngokudayela (844) 882-7841 (i-US kunye neCanada) okanye (574) 990-9828 (yamazwe ngamazwe). Ikhowudi yokudlula yomnxeba wenkomfa ngu-4648498. Ukufikelela kwi-webcast ephilayo kunye nentetho yesilayidi ehamba nayo, okanye ukurekhoda okulandelayo, nceda undwendwele icandelo labaTyali-mali lewebhusayithi ye-AVEO ku. www.aveooncology.com. Usasazo lwewebhu luya kurekhodwa kwaye lufumaneke ukuze ludlalwe kwakhona kwiwebhusayithi ye-AVEO kangangeeveki ezimbini.

Malunga FOTIVDA^® (tivozanib)

FOTIVDA^® (tivozanib) ngumlomo, isizukulwana esilandelayo se-vascular endothelial growth factor receptor (VEGFR) i-tyrosine kinase inhibitor (TKI). I-inhibitor enamandla, ekhethiweyo ye-VEGFRs 1, 2, kunye ne-3 enesiqingatha sobomi obude eyenzelwe ukuphucula ukusebenza kunye nokunyamezela. I-AVEO ifumene imvume ye-US Food and Drug Administration (FDA) ye-FOTIVDA nge-10 kaMatshi, ngo-2021 kunyango lwabaguli abadala ababuyela umva okanye abachasayo. Iseli ye-renal carcinoma (RCC) ngokulandela iindlela ezimbini okanye ngaphezulu zonyango lwenkqubo yangaphambili. I-FOTIVDA yamkelwa ngo-Agasti 2017 kwi-European Union kunye namanye amazwe akwintsimi yeqabane layo i-EUSA Pharma (UK) Limited kunyango lwezigulane zabantu abadala abane-RCC ephezulu. I-FOTIVDA ibonakaliswe ukunciphisa kakhulu imveliso ye-T-cell elawulayo kwiimodeli zangaphambili¹. I-FOTIVDA yafunyanwa nguKyowa Kirin.

INDICATION

I-FOTIVDA iboniswa kunyango lwezigulane ezikhulileyo ezine-relapsed renal cell carcinoma (RCC) ezilandela ezimbini okanye ngaphezulu zonyango lwangaphambili lwenkqubo.

IINKCUKACHA EZIBALULEKILEYO ZOKHUSELEKO

Izilumkiso kunye namanyathelo

Uxinzelelo lwegazi kunye neNgxaki yeHypertensive: Lawula uxinzelelo lwegazi ngaphambi kokuba uqalise i-FOTIVDA. Beka iliso kuxinzelelo lwegazi kwaye unyange njengoko kufuneka. Uxinzelelo lwegazi oluqhubekayo nangona ukusetyenziswa kweyeza ezichasayo, ukunciphisa umthamo we-FOTIVDA.

Ukungaphumeleli kweNtliziyo: Ukubeka iliso kwiimpawu okanye iimpawu zokungaphumeleli kwentliziyo kulo lonke unyango nge-FOTIVDA.

I-Ischemia ye-Cardiac kunye ne-Arterial Thromboembolic Events: Beka esweni izigulane ezisemngciphekweni owongeziweyo wezi ziganeko. Yeka ngokusisigxina i-FOTIVDA kwiziganeko ezinzima ze-arterial thromboembolic, ezifana ne-myocardial infarction kunye ne-stroke.

Iziganeko zeVenus Thromboembolic: Beka esweni izigulane ezisemngciphekweni owongeziweyo wezi ziganeko. Yeka ngokusisigxina i-FOTIVDA kwiziganeko ezinzima ze-venous thromboembolic.

Iziganeko Zokopha: Zibeke esweni izigulana ezisemngciphekweni okanye ezinembali yokopha.

Iproteinuria: Beka iliso kulo lonke unyango nge-FOTIVDA. Kwi-proteinuria ephakathi ukuya kwenzima, yehlisa umthamo okanye uphazamise okwethutyana unyango nge-FOTIVDA.

Ukungasebenzi kakuhle kweThyroid: Beka esweni phambi kokuba uqalise kwaye kulo lonke unyango nge-FOTIVDA.

Umngcipheko wokuPhiliswa kwenxeba: Bamba i-FOTIVDA ubuncinci iintsuku ezingama-24 ngaphambi kotyando olukhethiweyo. Musa ukulawula ubuncinane iiveki ezi-2 emva kotyando olukhulu kunye nokuphiliswa kwenxeba okwaneleyo. Ukhuseleko lokuqalisa kwakhona kwe-FOTIVDA emva kokusonjululwa kweengxaki zokuphulukisa isilonda akukasungulwa.

IReversible Posterior Leukoencephalopathy Syndrome (RPLS): Yeka i-FOTIVDA ukuba iimpawu okanye iimpawu ze-RPLS zenzeka.

I-Ebryo-Fetal Toxicity: Inokubangela ukwenzakala kumntwana ongekazalwa. Cebisa izigulane ngomngcipheko onokubakho kumntwana ongekazalwa kunye nokusebenzisa uqingqo-nzala olusebenzayo.

Iimpendulo ze-Alergic kwi-Tatrazine: I-0.89 mg capsule ye-FOTIVDA iqulethe i-FD & C Yellow No.5 (tartrazine) enokubangela ukusabela kohlobo oluthile (kuquka i-asthma ye-bronchial) kwizigulane ezithile ezithintekayo.

IZIPHUMO EZIBONAKALAYO

Ezona mpendulo zixhaphakileyo (≥20%) zazikudinwa, uxinzelelo lwegazi, urhudo, ukuncipha kokutya, isicaphucaphu, idysphonia, i-hypothyroidism, ukukhohlela, kunye ne-stomatitis, kunye neBanga lesi-3 okanye le-4 elingaqhelekanga lebhubhoratri (≥5%) yehla isodium, i-lipase yanda, kwaye i-phosphate yehla.

UKUSETYENZISWA KWEZIYOBISI

Ii-CYP3A4 Inducers ezinamandla: Gwema ukulawulwa ngokubambisana kwe-FOTIVDA kunye nee-inducers ezinamandla ze-CYP3A4.

UKUSETYENZISWA KWABANTU ABAKHETHEKILEYO

Ukuncancisa: Cebisa ukuba ungancancisi.
Abasetyhini kunye namadoda anamandla okuzala: Ingaphazamisa ukuchuma.
Ukuphazamiseka kweHepatic: Lungisa idosi kwizigulane ezinokukhubazeka okuphakathi kwesibindi. Gwema ukusetyenziswa kwizigulane ezinokukhubazeka okukhulu kwesibindi.

Ukunika ingxelo nge-SUSPECTED ADVERSE RECTIONS, qhagamshelana ne-AVEO Pharmaceuticals, Inc. kwi-1-833-FOTIVDA (1-833-368-4832) okanye i-FDA kwi-1-800-FDA-1088 okanye www.fda.gov/iswatch.

Nceda ujonge i-FOTIVDA Ulwazi olugcweleyo lokumisela olufumanekayo www.AVEOoncology.com.

Malunga Advanced Renal Cell Carcinoma

Ngokwezibalo ze-American Cancer Society's 2021, i-renal cell carcinoma (RCC) lolona hlobo luxhaphakileyo lomhlaza wezintso, ophakathi kwezona zomhlaza zixhaphakileyo kumadoda nabasetyhini. Malunga nama-73,750 amatyala amatsha omhlaza wezintso aya kufunyaniswa ngonyaka kwaye malunga ne-14,830 abantu abaza kubhubha sesi sifo. Kwizigulane ezinesifo sexesha elide, izinga lokusinda leminyaka emihlanu li-13%. Iiarhente ezijolise kwi-vascular endothelial growth factor (VEGF) indlela ibonise umsebenzi omkhulu we-antitumor kwi-RCC.² Ngokopapasho luka-2019, i-50% yezigulana ezimalunga ne-10,000 eziqhubela phambili emva kweendlela ezimbini okanye ngaphezulu zonyango zikhetha ukungalufumani olunye unyango,³ enokuthi ibangelwe yinkxalabo yokunyamezela kunye nokungabikho kwedatha yokuxhasa izigqibo zonyango ezisekelwe kubungqina kule meko yezigulane ezibuyele kakhulu okanye ezichasayo.

Malunga ne-AVEO Pharmaceuticals, Inc.

I-AVEO yinkampani egxile kwi-oncology egxile kwi-biopharmaceutical ezinikele ekuhambiseni amayeza anika ubomi obungcono kwizigulana ezinomhlaza. Isicwangciso se-AVEO kukugxila kwimithombo yayo ekuphuhliseni nasekurhwebeni kwabaviwa bayo bemveliso kuMntla Melika, ngelixa i-leveraging intsebenziswano ukuxhasa uphuhliso kunye norhwebo kwezinye iindawo. Umgqatswa okhokelayo we-AVEO, FOTIVDA^® (tivozanib), ifumene imvume ye-US Food and Drug Administration (FDA) ngo-Matshi 10, 2021 kunyango lwezigulane ezikhulileyo ezine-relapsed renal cell carcinoma (RCC) ezilandela iindlela ezimbini okanye ngaphezulu zonyango lwenkqubo. FOTIVDA^® yavunywa ngo-Agasti 2017 kwi-European Union kunye namanye amazwe kummandla we-EUSA kunyango lwezigulane zabantu abadala abane-RCC ephezulu. I-AVEO ibikhe yaxela kwangaphambili ngedatha yeklinikhi ethembisayo kwi-ficlatuzumab (i-anti-HGF IgG1 mAb) kumhlaza wentloko kunye nentamo, umhlaza wepancreatic kunye ne-acute myeloid leukemia kwaye iqhuba uvavanyo lwekliniki olungenamkhethe lweSigaba se-2 se-ficlatuzumab kunyango olunokubakho lomhlaza wentloko kunye nentamo. . Umbhobho we-AVEO wabaviwa bemveliso ikwabandakanya i-AV-380 (anti-GDF15 IgG1 mAb). I-AVEO iye yaxela ngaphambili ukwamkelwa kwesicelo sayo esitsha sophando e-US ye-AV-380 kunye nokuqaliswa kwayo kweSigaba soku-1 solingo lwezonyango lonyango olunokubakho lwe-cachexia yomhlaza. Umbhobho we-AVEO wangaphambili uquka izilwa-buhlungu ze-monoclonal kuphuhliso lwe-oncology, kuquka i-AV-203 (i-anti-ErbB3 mAb) kunye ne-AV-353 (i-anti-Notch 3 mAb). I-AVEO izibophelele ekudaleni imeko yeyantlukwano kunye nokubandakanywa.

Isilumkiso malunga neeNgxelo zokuJonga Phambili

Olu shicilelo losasazo luqulethe iingxelo ezijonge phambili ze-AVEO ngaphakathi kwentsingiselo yoMthetho woHlengahlengiso lweZibambiso zaBucala ka-1995 obandakanya umngcipheko omkhulu kunye nokungaqiniseki. 

Zonke iinkcazo, ngaphandle kweengxelo zenyaniso yembali, eziqulethwe kolu shicilelo lweendaba ziingxelo ezijonge phambili. Amagama athi “ukulindela,” “kholwa,” “lindela,” “nethemba,” “nenjongo,” “usenokuba,” “ceba,” “unokwenzeka,” “unokuba,” “ufanele,” “ufanele,” “ufuna,” “ukufuna,” “usenokufuna” "ukukhangela phambili," "ukuhamba phambili," "injongo," "iqhinga," okanye i-negative yala magama okanye ezinye iintetho ezifanayo, zenzelwe ukuchonga iingxelo ezijonge phambili, nangona ingezizo zonke iinkcazo ezikhangele phambili eziqulethe la magama okuchonga. 

Ezi nkcazo ezijonge phambili zibandakanya, phakathi kwezinye, iinkcazo malunga: Ixesha le-AVEO elicwangcisiweyo lokwenza i-FOTIVDA ifumaneke kwizigulane zase-US; amandla e-FOTIVDA njengendlela yokonyango kwizigulane ezine-relapsed/refractory or advanced RCC; ukusebenza okunokwenzeka, ukhuseleko, kunye nokunyamezela kwe-FOTIVDA, zombini njengomviwa weziyobisi ozimeleyo kunye nokudibanisa ne-immunotherapy; Ukuphunyezwa kwe-AVEO yesicwangciso sayo sonyango kunye nolawulo lwe-FOTIVDA; Izicwangciso kunye nezicwangciso ze-AVEO zolingo lwezonyango lwangoku kunye nexesha elizayo lwe-FOTIVDA, i-ficlatuzumab kunye ne-AV-380 kunye norhwebo lwe-FOTIVDA e-United States; ukuqhubela phambili kombhobho we-AVEO, kubandakanywa ukuqhubela phambili kwe-ficlatuzumab kwizifundo ezininzi zeklinikhi; ukusebenza okunokwenzeka, ukhuseleko kunye nokunyamezeleka kwe-ficlatuzumab, zombini njengomviwa weyeza elizimeleyo kunye nangokudityaniswa nolunye unyango; iziphumo ezinokwenzeka ezivela kwizifundo ze-ficlatuzumab ukubonelela i-AVEO ngamathuba okulandela izicwangciso zokulawula; usetyenziso lwezonyango olunokubakho lwe-ficlatuzumab kwiindawo ezinesidingo esingafezekanga; kunye neqhinga le-AVEO, okulindelweyo, izicwangciso kunye neenjongo zabagqatswa bayo bemveliso kunye neNkampani ngokubanzi. 

I-AVEO iseke ulindelo lwayo kunye noqikelelo kwiintelekelelo ezinokuthi zingqineke zingachanekanga. Ngenxa yoko, abafundi bayalunyukiswa ukuba bangathembeli ngokungafanelekanga kolu lindelo kunye noqikelelo. 

Iziphumo ezizizo okanye iziganeko zinokwahluka ngokwezinto ezibonakalayo kwizicwangciso, iinjongo kunye nolindelo oludizwe kwiingxelo ezijonge phambili ezenziwa yi-AVEO ngenxa yezinto ezininzi ezibalulekileyo, kubandakanywa nemingcipheko enxulumene: Ikhono le-AVEO lokuphumeza ngempumelelo izicwangciso zayo zobuchule, kubandakanywa amandla ayo ukurhweba ngempumelelo kwe-FOTIVDA kunye nokufumana kunye nokugcina imakethi kunye nokwamkelwa komhlawuli we-FOTIVDA; Ukukwazi kwe-AVEO ukunyusa imali eninzi eyongezelelweyo efunekayo ukuthengisa ngempumelelo iFOTIVDA; Amandla e-AVEO, kunye nokubanakho kwabo banamaphepha-mvume abo, ukubonisa ukwaneliseka kwee-arhente zolawulo ezisebenzayo ezifana ne-FDA ukhuseleko, ukusebenza kakuhle kunye noncedo olunentsingiselo ngokwezonyango lwabagqatswa bemveliso ye-AVEO, kunye nemingcipheko enxulumene nexesha kunye neendleko zokufuna kunye nokufumana imvume yokulawula. ; Ukuxhomekeka kwe-AVEO kubathengisi beqela lesithathu kuphuhliso, ukwenziwa kunye nokubonelela nge-FOTIVDA kunye nabaviwa bayo bemveliso; Ukukwazi kwe-AVEO ukungena kunye nokugcina intsebenziswano yomntu wesithathu kunye nezivumelwano zelayisensi, kunye nokukwazi kwayo, kunye nokukwazi kwamaqabane ayo anobuchule, ukuphumeza iinjongo zophuhliso kunye nezorhwebo phantsi kwala malungiselelo; I-AVEO kunye namandla okubambisene nabo babhalise ngempumelelo kwaye bagqibezele iimvavanyo zeklinikhi; Ukukwazi kwe-AVEO ukugcina ukuthotyelwa kweemfuneko zolawulo ezisebenzayo kwi-FOTIVDA kunye nabagqatswa bayo bemveliso; Ukukwazi kwe-AVEO ukufumana nokugcina ukhuseleko olwaneleyo kumalungelo epropathi enomgangatho ophezulu wokuqonda ngokunxulumene neFOTIVDA kunye nabagqatswa bayo bemveliso; iimfuno zenkunzi ezingacwangciswanga; ukungaqiniseki okunxulumene nokukwazi kwe-AVEO ukufikelela kwimali-mboleko yexesha elizayo phantsi kwesibonelelo semali-mboleko ye-Hercules, ejika impumelelo yeziganeko ezibalulekileyo ezinxulumene nokuvunywa kunye norhwebo lwe-FOTIVDA e-US; iimeko zoqoqosho, ezopolitiko kunye nezoshishino jikelele; iziphumo ezibi ezinokubakho zobhubhani we-COVID-19 kukuqhuba kweshishini le-AVEO, imeko yezemali, iziphumo zokusebenza, ukungakwazi ukuhlawula amatyala kunye nokukwazi ukubhalisa ngempumelelo nangexesha, ukugqiba kunye nokufunda idatha evela kulingo lwezonyango; izinto ezikhuphisanayo; kunye nezo mngcipheko ezixoxwe kumacandelo anesihloko esithi "Izinto zoMngcipheko" kunye ne "Ingxoxo yoLawulo kunye noHlalutyo lweMeko yezeMali kunye neZiphumo zeMisebenzi-Liquidity kunye neMithombo yeNkunzi" ezibandakanyiweyo kwiingxelo zekota kunye zonyaka ze-AVEO kwifayile kunye neKhomishini yezoKhuseleko kunye noTshintsho (SEC) kunye kwezinye iifayili ezenziwa yi-AVEO kunye ne-SEC. 

Iingxelo ezijonge phambili kolu shicilelo lweendaba zimele iimbono ze-AVEO ukususela kumhla wokupapashwa kweendaba, kwaye iziganeko ezilandelayo kunye nophuhliso lunokubangela ukuba iimbono zayo zitshintshe. 

Ngelixa i-AVEO inokukhetha ukuhlaziya ezi nkcazo ezijonge phambili kwixesha elizayo, iyayikhupha ngokukodwa nayiphi na imbopheleleko yokwenza njalo. Akufanele, ke ngoko, ungathembeli kwezi nkcazo zokujonga phambili njengoko zimele iimbono ze-AVEO njengawo nawuphi na umhla ngaphandle komhla wokukhutshwa kweendaba.

Nayiphi na ireferensi yedilesi yewebhusayithi ye-AVEO kolu shicilelo lweendaba yenzelwe ukuba ibe yireferensi yombhalo ongasebenziyo kuphela kwaye ingabi yi-hyperlink esebenzayo.

Iingxelo:

1. Pawlowski N et al. I-AACR 2013. Ipowusta 3971
2. J Angulo kunye no-O Shapiro, iiCancer (Basel) 2019 Sep; 11(9): 1227. [10.3390/umhlaza11091227]
3. Izibonelelo zezigqibo. Ubume be-RCC kunye noqikelelo. NgoDisemba 12, 2019.